S-288310

derived from both DEPDC1 and MPHOSPH1 proteins

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

1.	Neoplasms (Cancer) 01/01/2017 - "A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder." 01/01/2017 - "S-288310, a cancer peptide vaccine composed of two HLA-A*24:02-restricted peptides derived from two oncoantigens, DEP domain-containing 1 (DEPDC1) and M-phase phosphoprotein 1 (MPHOSPH1), was investigated in urothelial carcinoma (UC) of the bladder. "
2.	Carcinoma (Carcinomatosis) 01/01/2017 - "A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder." 01/01/2017 - "S-288310, a cancer peptide vaccine composed of two HLA-A*24:02-restricted peptides derived from two oncoantigens, DEP domain-containing 1 (DEPDC1) and M-phase phosphoprotein 1 (MPHOSPH1), was investigated in urothelial carcinoma (UC) of the bladder. "
3.	Injection Site Reaction 01/01/2017 - "Of 32 patients receiving S-288310 in the phase II, the most frequent drug-related AE was the injection site reaction that was observed in 29 patients (90.6%), but none of the patients discontinued administration due to these reactions and no dose relationship in the frequency and severity was observed. "

1.	Protein Subunit Vaccines
2.	Phosphoproteins
3.	Peptides (Polypeptides)
4.	HLA-A*24:02 antigen
5.	1-(2-(dodecyloxy)ethyl)pyrrolidine hydrochloride (DEP)